HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $80

Benzinga · 10/18 11:13
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $45 to $80.